[{"orgOrder":0,"company":"Muvon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence Using a Novel Regenerative Cell Therapy","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Muvon Therapeutics"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Imbrium Therapeutics"},{"orgOrder":0,"company":"Glycologix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Glycologix"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
GLX-100 is a novel biopolymer, which has been designed to closely replicate the natural protective barrier layer and relieve the symptoms of Interstitial Cystitis/Bladder Pain Syndrome and Phase I results anticipated in 2024.
IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
To investigate safety and feasibility of a tissue-regenerative approach to treat stress urinary incontinence (SUI) in female patients with a novel transurethral injection therapy using autologous MPCs in a combination with NMES.
Lead Product(s):
Autologous Muscle Precursor Cell Therapy